ライフサイエンスコーパス: soluble tumor necrosis factor receptor

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 erleukin-1 receptor antagonist (sIL-1ra) and soluble tumor necrosis factor receptor 1 (sTNF-R1).

2 ble CD14 level, kynurenine/tryptophan ratio, soluble tumor necrosis factor receptor 1 level, high-sen

3 in-6, C-reactive peptide, interleukin-8, and soluble tumor necrosis factor receptor 1 were most diffe

4 leukin (IL)-1 receptor antagonist (sIL-1ra), soluble tumor necrosis factor receptor 1, soluble vascul

5 rkers C-reactive protein, interleukin 6, and soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1

6 or (t-PA), LDL-C, von Willebrand factor, and soluble tumor necrosis factor receptors 1 and 2.

7 and plasma interleukin-6, interleukin-8, and soluble tumor necrosis factor receptor-1 levels were sig

8 y volunteer levels and reduced inflammation (soluble tumor necrosis factor receptor-1), coagulation (

9 uced set of three biomarkers (interleukin-8, soluble tumor necrosis factor receptor-1, and surfactant

10 angiopoietin-1, angiopoietin-2, IL-6, IL-8, soluble tumor necrosis factor receptor-1, soluble vascul

11 nd factor antigen, surfactant protein-D, and soluble tumor necrosis factor receptor-1, which are biom

12 e protein (CRP), interleukin (IL)-6, and the soluble tumor necrosis factor receptor 2 (sTNFR-2) in bl

13 erval [CI], 1.7-4.2; Ptrend = 1.0 x 10(-6)), soluble tumor necrosis factor receptor 2 (sTNFR2; OR, 3.

14 n inflammatory process dominated by markers: soluble tumor necrosis factor receptor 2, soluble interl

15 ed that levels of leptin, interleukin-6, and soluble tumor necrosis factor receptor-2, as well as the

16 uch as interleukin-1 receptor antagonist and soluble tumor necrosis factor receptors, and is protecti

17 levels approximately 2-fold (P=.03), whereas soluble tumor necrosis factor receptor blunted the incre

18 We evaluated etanercept, a human soluble tumor necrosis factor receptor: Fc fusion protei

19 Etanercept, a soluble tumor necrosis factor receptor, has been shown t

20 soluble interleukin 6 receptor (sIL-6R), and soluble tumor necrosis factor receptor I (sTNF-RI) were

21 T cells, plasma interleukin 6 (IL-6) level, soluble tumor necrosis factor receptor I (sTNFR-I) level

22 a, C4a, C5a), cytokines (IL-2, IL-6, IL-10), soluble tumor necrosis factor receptor I, and platelet a

23 tein, tumor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-R

24 r 1 or its binding protein) or inflammation (soluble tumor necrosis factor receptors I or II).

25 ve protein (r=0.28), interleukin-6 (r=0.22), soluble tumor necrosis factor receptor II (r=0.22), solu

26 s tested for levels of interleukin-6 (IL-6), soluble tumor necrosis factor receptor II (sTNFRII) (as

27 i-CCP) antibodies, interleukin-6 (IL-6), and soluble tumor necrosis factor receptor II (sTNFRII).

28 ected by pregnancy or infection, circulating soluble tumor necrosis factor receptor II was highest in

29 Etanercept, a dimerized version of the soluble tumor necrosis factor receptor II, and inflixima

30 nsitivity C-reactive protein, interleukin 6, soluble tumor necrosis factor receptor II, soluble inter

31 mum plasma levels of interleukin (IL)-10 and soluble tumor necrosis factor receptor-II correlated wit

32 2 receptor, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptors p55 and p75.

33 ted the safety and efficacy of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion p

34 ermine whether the addition of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion p

35 When soluble tumor necrosis factor receptor (sTNFR) I and II

36 To investigate whether circulating levels of soluble tumor necrosis factor receptors (sTNFR) are pred

37 tumor necrosis factor-[alpha], type I and II soluble tumor necrosis factor receptors (sTNFR-I and -II

38 (IL-6), soluble IL-6 receptor (sIL-6R), and soluble tumor necrosis factor receptors (sTNFRI and -II)

39 Plasma levels of 80-kDa soluble tumor necrosis factor receptors (sTNFRs) were hi

40 s factor-alpha with monoclonal antibodies or soluble tumor necrosis factor receptor substantially red

41 Plasma concentrations of soluble tumor necrosis factor receptor superfamily 1A (s

42 Exogenous soluble tumor necrosis factor receptor (TNFR) has been s

43 Recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) is a di

44 Soluble tumor necrosis factor receptors (TNFRs) are impo

45 of tumor necrosis factor-alpha (TNF-alpha), soluble tumor necrosis factor receptor type I (sTNFR-I),

46 crosis factor receptor type I (sTNFR-I), and soluble tumor necrosis factor receptor type II (sTNFR-II

47 pha (TNF-alpha) concentrations and increased soluble tumor necrosis factor receptor type II (sTNFRII)

48 , such as serum levels of interleukin-10 and soluble tumor necrosis factor receptors types Iota and I

49 ive protein, temperature, interleukin 8, and soluble tumor necrosis factor receptor were also reduced

50 of the other soluble adhesion molecules and soluble tumor necrosis factor receptor were not signific

51 Also, the plasma concentrations of soluble tumor necrosis factor receptors were higher in I

52 Levels of soluble tumor necrosis factor receptors were higher in t

53 as selective cyclooxygenase-2 inhibitors and soluble tumor necrosis factor receptor, whose developmen

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。